POM-V Prescription Required

Arti-Cell Forte Suspension for Injection for Horses

Active ingredient: Chondrogenic induced equine allogeneic peripheral blood-derived mesenchymal stem cells

Form

Injection

Species

Horses

Manufacturer

Boehringer Ingelheim Vetmedica GmbH

VMD MA No.

04491/5062

What it's used for

Reduction of mild to moderate recurrent lameness associated with non-septic joint inflammation in horses.

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Chondrogenic induced equine...

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Arti-Cell Forte Suspension for Injection for Horses — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

Reduction of mild to moderate recurrent lameness associated with non-septic joint
inflammation in horses.

Route of administration:
Intraarticular use.
Dosage:
A single intraarticular injection of 1 dose (2 ml) per animal.
Preparation of the suspension for injection:
The veterinary product must be administered intraarticularly by a veterinary surgeon
taking special precautions to ensure sterility of the injection process. The product
must be manipulated and injected using sterile techniques and in a clean
environment.
The product needs to be administered immediately after thawing to prevent
significant cell death.
Using appropriate gloves, remove the two vials (one vial of cells (1 ml) and one vial
of EAP (1ml)) from the freezer/liquid nitrogen and thaw immediately at 25 °C – 37 °C,
e.g. in a water bath, until the contents in each are completely thawed (approximately
5 minutes).
If any cell clusters are visible in either of the vials after thawing, gently shake the vial
concerned until the suspension is clear and colourless (stem cell suspension) or
clear and yellow (equine allogeneic plasma suspension: the diluent).
Remove the cap of the vial that thawed first and aspirate the suspension in a syringe,
then remove the cap of the other (thawed) vial and aspirate the suspension in the
same syringe. Then mix both the suspensions in the same syringe to produce one
dose of the product (2 ml).
Use a needle with a diameter greater than or equal to 22G in order to prevent cell
damage.

Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.

Mild increases in lameness and injection site reactions, such as mild to moderate
increases in joint swelling and mild increases in temperature at the injection sites,
occurred very commonly in the first week after use of the product. In the pivotal
clinical field study a single systemic administration of an NSAID was given
concurrently to treatment with Arti-Cell Forte.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

The product has been demonstrated to be efficacious in horses showing mild to
moderate lameness in the fetlock joint.

Unlimited Renewal: October 2023
AN: 02136/2023
Efficacy data are not available regarding treatment of other joints.
The efficacy of the product was demonstrated in a pivotal field trial after single
administration of the product and concurrent single systemic administration of an
NSAID. According to the benefit-risk assessment of the responsible veterinarian of
the individual case a single dose systemic NSAID may be administered on the day of
intraarticular injection.

Special precautions for use in animals
In order to avoid thrombosis in small vessels when administering intraarticular
injections the correct placement of the needle is critical.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Liquid nitrogen containers should be handled by properly trained personnel only. The
handling of liquid nitrogen should take place in a well-ventilated area. Before
withdrawing the vials from the liquid nitrogen canister, protective equipment
consisting of gloves, long sleeves and a facemask or goggles should be worn.
In case of accidental self-injection this product can cause pain, local inflammatory
reactions and swelling at the site of injection which may persist for several weeks and
possibly cause fever, seek medical advice immediately and show the package leaflet
or the label to the physician.

No data available.
Do not administer simultaneously with any other intraarticular veterinary medicinal
product.

Store and transport frozen (
–
90 °C to
–
70 °C) or in liquid nitrogen.

Unlimited Renewal: October 2023
AN: 02136/2023

Zero days.

Unlimited Renewal: October 2023
AN: 02136/2023
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.